Takeaway

• A novel chimeric antigen receptor (CAR) T-cell demonstrated favorable safety and preliminary signs of efficacy in patients with solid tumors as a monotherapy and in combination with an mRNA vaccine (CARVac).

Why this matters

• CAR T-cell therapy has been largely successful in the management of hematologic malignancies; however, its utility...